Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Window-of-opportunity Trial of Nivolumab and BMS-986205 in HNSCC
NCT03854032Phase 2Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linrodostat in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Thomas Jefferson University. Started Apr 2019; status: terminated.
02
Drugs
linrodostat
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03854032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854032.